Increasing the number of clinical trials available to adolescents diagnosed with cancer

Pediatrics

Volumn 133, Issue SUPPL. 3, 2014, Pages

  Gupta, Abha A ^a   Indelicato, Daniel J ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Adolescent oncology

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; ASTROCYTOMA; BLADDER CARCINOMA; CANCER STAGING; CHONDROSARCOMA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COLORECTAL CARCINOMA; COOPERATION; EPENDYMOMA; EWING SARCOMA; FIBROMA; FUNDING; GERM CELL TUMOR; GLIOBLASTOMA; GONAD TUMOR; HEALTH CARE PERSONNEL; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CARCINOMA; MEDULLOBLASTOMA; MELANOMA; NASOPHARYNX CARCINOMA; NEOPLASM; NONHODGKIN LYMPHOMA; OROPHARYNX CARCINOMA; OSTEOSARCOMA; PATIENT PARTICIPATION; PRIORITY JOURNAL; RHABDOMYOSARCOMA; THYROID CARCINOMA; UTERINE CERVIX CARCINOMA; UTERUS CARCINOMA;

ADOLESCENT ONCOLOGY;

ADOLESCENT; CLINICAL TRIALS AS TOPIC; HEALTH SERVICES ACCESSIBILITY; HUMANS; NEOPLASMS; SURVIVAL RATE;

EID: 84901759266     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-0122G     Document Type: Article

References (18)

1. Bleyer WA, Tejeda H, Murphy SB, et al. National cancer clinical trials: children have equal access; adolescents do not. J Adolesc Health. 1997;21(6):366-373 (Pubitemid 27514842)
2. Parsons HM, Harlan LC, Seibel NL, Stevens JL, Keegan TH. Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference? J Clin Oncol. 2011;29(30):4045-4053
3. Bleyer A, O'Leary M, Barr R, Ries LAG, eds. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, including SEER Incidence and Survival: 1975-2000. Bethesda, MD: National Cancer Institute; 2006
4. Bleyer WA. Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival, and importance of clinical trials. Med Pediatr Oncol. 2002;38(1):1-10 (Pubitemid 34037707)
5. Gupta AA, Anderson JR, Pappo AS, et al. Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Cancer. 2012;118(4):1130-1137
6. De P, Ellison LF, Barr RD, et al Steering Committee for Canadian Cancer Statistics. Canadian adolescents and young adults with cancer: opportunity to improve coordination and level of care. CMAJ. 2011;183(3):E187-E194
7. Nichols CR, Roth B, Kollmannsberger C. Classical clinical trial design in testicular cancer: time to move on. J Clin Oncol. 2012;30(8):769-771
8. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER*Stat Database: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Sub (1973-2009 varying)-Linked To County Attributes-Total U.S., 1969-2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based on the November 2011 submission. Available at: www.seer.cancer.gov. Accessed April 28, 2013
9. Bleyer A, Siegel SE, Coccia PF, Stock W, Seibel NL. Children, adolescents, and young adults with leukemia: the empty half of the glass is growing. J Clin Oncol. 2012;30(32):4037-4038, author reply 4038-4039
10. Stock W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:21-29
11. Breitenbach K, Stock W. Intergroup Trial C10403: a pediatric treatment approach to improve outcomes in adolescents and young adults with acute lymphoblastic leukemia. J Adolesc Young Adult Oncol. 2011;1:107-108
12. Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer. 2012;59(1):5-10
13. Bielack SS, Smeland S, Whelan J, Marina N, Hook J, Jovic G, et al. MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 " good response" randomization. 2013 ASCO Annual Meeting Abstracts. J Clin Oncology. 2013;31(June 20 Supplement): LBA10504
14. Doroshow JH, Sleijfer S, Stupp R, Anderson K. Cancer clinical trials-do we need a new algorithm in the age of stratified medicine? Oncologist. 2013;18(6):651-652
15. National Cancer Institute. National Clinical Trails Network Program Guidelines D. Available at: http://ctep.cancer.gov/investigatorResources/docs/ NCTN-Program-Guidelines.pdf. Accessed August 12, 2013
16. Establishment of New Adult CIRB RCAChwnoFREMpAA, 2013. Available at: https://ncicirb.org/cirb/documents/FINAL-RollOut-EPE-Memo-072613.pdf. Accessed April 14, 2014
17. National Cancer Institute. Central institutional review board independent model information. Available at: https://ncicirb.org/cirb/independentModelInfo. action. Accessed April 14, 2014
18. US Food and Drug Administration. Advisory Committee for Pharmaceutical Science and Clinical Pharmacology Meeting, March 14, 2012, National Harbor, MD. Available at: www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ AdvisoryCommitteeforPharmaceuticalScienceandClinical-Pharmacology/UCM298465.pdf. Accessed April 28, 2013